Search

Your search keyword '"Tamai, Toshiyuki"' showing total 250 results

Search Constraints

Start Over You searched for: Author "Tamai, Toshiyuki" Remove constraint Author: "Tamai, Toshiyuki"
250 results on '"Tamai, Toshiyuki"'

Search Results

4. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT StudyBiomarker Analysis Following Lenvatinib in Unresectable HCC

5. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

6. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

7. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

8. Analysis of tumor biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) from a phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, in combination with lenvatinib.

11. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

16. A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.

18. 'Fair M&A Guidelines' and MBOs

21. Abstract CT523: An open-label, multicenter, phase 1b/2 Study of E7386 (Wnt/β-catenin pathway inhibitor) + pembrolizumab in patients with pretreated advanced solid tumors

25. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

26. 'Fair M&A Guidelines' and Freezeout Transactions(2)

27. Helically aligned fused carbon hollow nanospheres with chiral discrimination ability

30. M&A Transactions and Injunctive Relief

33. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.

36. Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma

41. Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC).

42. Overall Survival and Objective Response in Advanced Unresectable Hepatocellular Carcinoma: A Subanalysis of the REFLECT Study

43. M&A Transactions and Injunctive Relief(2)

44. Generation of polyphenylene radical cations and their cosensitization ability in the 9,10-dicyanoanthracene-sensitized photochemical chain reactions of 1,2-bis(4-methoxyphenyl)cyclopropane

46. Photooxygenation of 1,omega-bis(diarylethenyl)alkanes via photoinduced electron-transfer: formation of 1,4-radical cations and its trapping by molecular dioxygen

47. Salt effect of the 9,10-dicyanoanthracene-sensitized photooxygenation of 1,2-diarylcyclopropanes and the photodecomposition of 3,5-diaryl-1,2-dioxolanes

48. Insertion of nitrogen oxide and nitrosonium ion into the cyclopropane ring: a new route to 2-isoxazolines and its mechanistic studies

49. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Catalog

Books, media, physical & digital resources